Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
2
20%
Ph phase_2
6
60%

Phase Distribution

2

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(2)
Other(2)

Detailed Status

Completed6
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 32 (20.0%)

Trials by Status

completed660%
terminated220%
unknown220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Navelbine And Radiotherapy in Locally Advanced Lung Cancer

NCT00887783
unknownphase_3

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

NCT04665986
terminatedphase_2

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
completedphase_2

Preoperative Herceptin and Navelbine for Breast Cancer

NCT00148681
unknownphase_2

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

NCT02489409
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00887783Phase 2

Navelbine And Radiotherapy in Locally Advanced Lung Cancer

Completed
NCT04665986Phase 3

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Unknown
NCT00632827Phase 2

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated
NCT00148681Phase 2

Preoperative Herceptin and Navelbine for Breast Cancer

Completed
NCT02489409Phase 2

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Unknown
NCT00148668Phase 2

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Completed
NCT00153907Phase 1

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Completed
NCT00004093Phase 1

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated
NCT00433095Phase 2

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Completed
NCT00148395Phase 3

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10